Cargando…

Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer

BACKGROUND: The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients is increased and often requires treatment or prophylaxis with direct oral anticoagulants (DOACs). Small-molecule inhibitors (SMIs) to treat NSCLC may cause relevant drug–drug interactions (DDIs) with DOACs. Guida...

Descripción completa

Detalles Bibliográficos
Autores principales: Otten, Leila S., Piet, Berber, van den Heuvel, Michel M., Marzolini, Catia, van Geel, Robin M.J.M., Gulikers, Judith L., Burger, David M., Leentjens, Jenneke, ter Heine, Rob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489148/
https://www.ncbi.nlm.nih.gov/pubmed/35705208
http://dx.doi.org/10.1183/16000617.0004-2022